TESARO,Inc. (NASDAQ:TSRO) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

0

TESARO,Inc. (NASDAQ:TSRO) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(e) TESARO,Inc. 2012 Employee Stock Purchase Plan

On May10, 2018, at the 2018 Annual Meeting of Stockholders (the “Annual Meeting”) of TESARO,Inc. (the “Company”), the stockholders approved an amendment (the “Amendment”) to the TESARO,Inc. 2012 Employee Stock Purchase Plan (the “ESPP”) to, among other things, increase the number of shares available for issuance thereunder by 275,000 shares. Descriptions of the Amendment and the ESPP are set forth in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April6, 2018 (the “Proxy Statement”) in the section entitled “Proposal No.4 — Approval of an Amendment to the 2012 Employee Stock Purchase Plan,” which is incorporated herein by reference. A copy of the Amendment is attached as Exhibit10.1 to this Current Report and is also incorporated herein by reference.

Item 5.07 Submission of Matters to a Vote of Security Holders.

The Annual Meeting was held on May10, 2018. As of March13, 2018, the date of record for determining the stockholders entitled to vote on the proposals presented at the Annual Meeting, there were 54,799,815 shares of Company common stock issued and outstanding and entitled to vote at the Annual Meeting. The holders of 49,253,539 shares of the Company’s issued and outstanding common stock were represented in person or by proxy at the Annual Meeting, constituting a quorum. The proposals are described in detail in the Proxy Statement. The vote results detailed below represent final results as certified by the Annual Meeting’s inspector of elections.

Proposal 1

The Company’s stockholders elected the following persons, who were listed in the Company’s proxy statement for the Annual Meeting, to the Company’s Board of Directors to hold office until the next annual meeting of stockholders or until their successors are elected and qualified or until his or her earlier death, resignation or removal:

VotesFor

VotesWithheld

BrokerNon-Votes

Leon O. Moulder,Jr.

44,701,404

99,077

4,453,058

Mary Lynne Hedley, Ph.D.

44,673,072

127,409

4,453,058

David M. Mott

38,551,387

6,249,094

4,453,058

Lawrence M. Alleva

44,414,210

386,271

4,453,058

James O. Armitage, M.D.

44,658,055

142,426

4,453,058

Earl M. (Duke) Collier,Jr.

44,647,599

152,882

4,453,058

Garry A. Nicholson

44,659,640

140,841

4,453,058

Kavita Patel, M.D.

44,660,863

139,618

4,453,058

Beth Seidenberg, M.D.

44,585,796

214,685

4,453,058

Pascale Witz

44,166,448

634,033

4,453,058

Proposal 2

The Company’s stockholders approved the TESARO,Inc., Non-Employee Director Compensation Policy, including compensation amounts for 2018. The votes regarding this proposal were as follows:

VotesFor

VotesAgainst

Abstentions

BrokerNon-Votes

27,560,555

17,153,193

86,733

4,453,058

Proposal 3

The Company’s stockholders approved, by non-binding vote, the Company’s executive compensation. The votes regarding this proposal were as follows:

VotesFor

VotesAgainst

Abstentions

BrokerNon-Votes

44,080,638

648,337

71,506

4,453,058

Proposal 4

The Company’s stockholders approved an amendment to the ESPP to, among other things, increase the number of shares available for issuance thereunder by 275,000 shares. The votes regarding this proposal were as follows:

VotesFor

VotesAgainst

Abstentions

BrokerNon-Votes

44,616,575

117,569

66,337

4,453,058

Proposal 5

The Company’s stockholders ratified the appointment of Ernst& Young,LLP as the Company’s independent registered public accounting firm for the fiscal year ending December31, 2018. The votes regarding this proposal were as follows:

VotesFor

VotesAgainst

Abstentions

BrokerNon-Votes

48,630,058

530,723

92,758

Section9 — Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits

(d) Exhibits


TESARO, Inc. Exhibit
EX-10.1 2 a18-13350_1ex10d1.htm EX-10.1 Exhibit 10.1   AMENDMENT TO THE TESARO,…
To view the full exhibit click here

About TESARO,Inc. (NASDAQ:TSRO)

TESARO, Inc. is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform. It offers VARUBI (rolapitant), which is an oral substance P/neurokinin 1 (NK-1) receptor antagonist for use in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy. It is developing IV formulation of rolapitant, which has completed various Phase 1 clinical trials. Its niraparib is an orally active and poly (ADP-ribose) polymerase (PARP) inhibitor. Its immuno-oncology platform has immuno-oncology programs, which include TSR-022 and TSR-042.